With preclinical, clinical, and translational research all happening under one
roof, we rapidly pursue the best ideas for slowing, stopping, and ending
ALS. Our cutting-edge approach has resulted in:
- The rigorous screening of over 400 potential treatments for ALS—more
than any other ALS research lab in the world.
Launched the ALS TDI's ALS Research Collaborative (ARC) –
an ambitious global initiative that is designed to accelerate ALS research by
gathering comprehensive data from people with ALS and sharing it with researchers
around the world.
- The world's first Precision Medicine Program, a partnership with
people living with ALS, designed to speed up drug discovery and
therapeutic development for ALS.
- ALS TDI becoming the first nonprofit biotech in any disease to develop a
tegoprubart, and bring it from our own
labs, through FDA review and into clinical trial.
- The improvement of worldwide standards in preclinical drug screening
in models of ALS.